株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

乳癌治療薬市場 - 世界の業界分析、規模、シェア、成長、動向、および2015〜2023年の予測

Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

発行 Transparency Market Research 商品コード 338034
出版日 ページ情報 英文 88 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
乳癌治療薬市場 - 世界の業界分析、規模、シェア、成長、動向、および2015〜2023年の予測 Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
出版日: 2015年11月25日 ページ情報: 英文 88 Pages
概要

レポートでは、乳癌治療薬市場について調査し、市場の動向と今後の見通し、市場の機会などのほか、地域別動向、および参入する主要企業のプロファイルなどをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と概要
  • 疫学とハイリスクグループ
  • 乳癌の診断と種類
  • その他の乳癌治療法
  • 市場動向
    • 促進因子
      • 高い発症率
      • 人口統計的移行
      • 肥満罹患率上昇
      • 診断スクリーニングプログラム
      • 民間医療保険プランの増加
    • 阻害因子
      • ジェネリック薬:ブランド薬の代用
      • 競争激化:価格低下
      • 薬剤コストの高さによるアクセスバリア
      • 社会健康保険の不備
      • 乳癌治療薬の深刻な副作用
      • 女性のエンパワーメントが不足する国
      • 新たな医学的オプション
    • 機会
      • 国内製薬会社の成長可能性
      • 併用薬剤治療法
      • 技術進歩と薬剤認可の動向
      • 新たなコンパニオン診断モデル
      • トリプルネガティブに対する薬剤治療
      • HER2乳癌に対する複合適応の人か
  • 市場の魅力度分析
  • 競合環境

第4章 市場セグメンテーション

  • 概要
  • HER2阻害剤市場収益
  • 分裂抑制剤市場収益
  • 代謝拮抗剤市場収益
  • アロマたーぜ阻害剤市場収益
  • ホルモン受容体市場収益

第5章 地域別市場

  • イントロダクション
  • 世界の乳癌治療薬市場収益
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第6章 提言

第7章 企業プロファイル

  • AstraZeneca plc
  • エーザイ株式会社
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global breast cancer therapeutics market with respect to the leading market segments in terms of geography.

The global breast cancer therapeutics market has been studied based on major drug class segments, and their regional as well as national markets. Based on drug class, the global market has been categorized into five major segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The market for these segments and sub-segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments, considering 2014 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is illustrated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.

Geographically, the breast cancer therapeutics market has been segmented into five regions: North America (the U.S. and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil and Rest of Latin America), and Middle East & Africa (MEA). Market revenue in terms of US$ Mn and CAGR % from 2015 to 2023 are provided for all the regions and countries, considering 2014 as the base year.

The recommendations section included in the report would assist existing market players in expanding their market shares and new pharmaceutical companies in establishing their presence in the global breast cancer market. The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The global breast cancer therapeutics market has been segmented as follows:

Global Breast Cancer Therapeutics Market, by Drug Class

  • Overview
  • Global HER2 Inhibitors Market Revenue, 2015-2023 (US$ Mn)
  • Herceptin (Trastuzumab)
  • Tykerb (Lapatinib)
  • Perjeta (Pertuzumab)
  • Kadcyla (Ado-trastuzumab emtansine)
  • Global Mitotic Inhibitors Market Revenue, 2015-2023 (US$ Mn)
  • Halaven (Eribulin)
  • Taxotere (Docetaxel)
  • Ixempra (Ixabepilone)
  • Global Anti-metabolites Market Revenue, 2015-2023 (US$ Mn)
  • Gemzar (Gemcitabine)
  • Global Aromatase Inhibitors Market Revenue, 2015-2023 (US$ Mn)
    • Femara (Leterozole)
    • Aromasin (Exemestane)
    • Arimidex (Anastrozole)
    • Ibrance (Palbociclib)
    • Afinitor (Everolimus)
  • Global Hormone Receptor Market Revenue, 2015-2023 (US$ Mn)
  • Zoladex
  • Faslodex
  • Fareston

Global Breast Cancer Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

  • 2.1. Global Breast Cancer Therapeutics: Market Snapshot
  • 2.2. Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
  • 2.3. Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023(Value %)

3. Global Breast Cancer Therapeutics Market - Market Overview

  • 3.1. Market Definition and Overview
  • 3.2. Epidemiology & High Risk Groups
  • 3.3. Diagnosis and Types of Breast Cancer
  • 3.4. Other Breast Cancer Therapies
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Higher Incidence Rate
      • 3.5.1.2. Demographic Transition
      • 3.5.1.3. Rising Prevalence Of Obesity
      • 3.5.1.4. Diagnostic Screening Programs
      • 3.5.1.5. Increase in Private Health Insurance Plans:
    • 3.5.2. Restraints
      • 3.5.2.1. Generic Drugs: Substitute Branded Drugs
      • 3.5.2.2. Intense Competition: Fall in Prices
      • 3.5.2.3. Access barriers due to high drug costs
      • 3.5.2.4. Absence of Social Health Insurance
      • 3.5.2.5. Serious Side Effects of Breast Cancer Therapeutics
      • 3.5.2.6. Countries Lacking Women Empowerment
      • 3.5.3.7. Newer medication options
    • 3.5.3. Opportunities
      • 3.5.3.1. Potential Growth of Domestic Pharmaceutical Companies
      • 3.5.3.2. Combination Drug Therapy
      • 3.5.3.3. Technological Advancements and Robust Trends of Drug Approval
      • 3.5.3.4. New Companion Diagnostics Models
      • 3.5.3.5. Drug Therapy for Triple Negative(TNBC)
      • 3.5.3.6. Approval for Multiple Indications(positive & negative types) HER2 breast cancer
  • 3.7. Market Attractiveness Analysis- Breast Cancer Therapeutics Market, by Geography(2014)(%)
  • 3.8. Competitive Landscape - Breast Cancer Therapeutics Market, by Key Players, 2014(%)

4. Market Segmentation - By Drug Class

  • 4.1. Overview
  • 4.2. Global HER2 Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.2.1. Herceptin(Trastuzumab)
    • 4.2.2. Tykerb(Lapatinib)
    • 4.2.3. Perjeta(Pertuzumab)
    • 4.2.4. Kadcyla(Ado-trastuzumab emtansine)
  • 4.3. Global Mitotic Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.3.1. Halaven(Eribulin)
    • 4.3.2. Taxotere(Docetaxel)
    • 4.3.3. Ixempra(Ixabepilone)
  • 4.4. Global Anti-metabolites Market Revenue, 2015-2023(US$ Mn)
    • 4.4.1. Gemzar(Gemcitabine)
  • 4.5. Global Aromatase Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.5.1. Femara(Leterozole)
    • 4.5.2. Aromasin(Exemestane)
    • 4.5.3. Arimidex(Anastrozole)
    • 4.5.4. Ibrance(Palbociclib)
    • 4.5.5. Afinitor(Everolimus)
  • 4.6. Global Hormone Receptor Market Revenue, 2015-2023(US$ Mn)
    • 4.6.1. Zoladex
    • 4.6.2. Faslodex
    • 4.6.3. Fareston

5. Market Segmentation - By Geography

  • 5.1. Introduction
  • 5.2. Global Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
  • 5.3. North America Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.3.1. U.S.
    • 5.3.2. Canada
  • 5.4. Europe Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.4.1. Germany
    • 5.4.3. U.K.
    • 5.4.4. Rest of Europe
  • 5.5. Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.5.1. Japan
    • 5.5.2. South Korea
    • 5.5.3. Rest of Asia Pacific
  • 5.6. Rest of the World
    • 5.6.1. Latin America
      • 5.6.1.1. Brazil
      • 5.6.1.2. Rest of Latin America
    • 5.6.2. Middle East and Africa

6. Recommendations

7. Company Profiles

  • 7.1. AstraZeneca plc
  • 7.2. Eisai Co., Ltd.
  • 7.3. Eli Lilly and Company
  • 7.4. F. Hoffmann-La Roche Ltd.
  • 7.5. GlaxoSmithKline plc
  • 7.6. Novartis International AG
  • 7.7. Pfizer, Inc.
  • 7.8. Puma Biotechnology, Inc.
  • 7.9. Sanofi S.A.
  • 7.10. Teva Pharmaceutical Industries Ltd.
Back to Top